| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
10% Owner
1 company
Panacea Innovation Ltd serves as a 10% Owner at ATRA. Across recent SEC filings that breaks down to 2 buys and 1 sell. Those positions are worth an estimated $11.2M at current prices.
Historically, Panacea Innovation Ltd's trades have earned a below-average insider score of 42/100 across 3 rated trades. Over a 12-month horizon, 0.0% of those trades were profitable, with an average 12-month return of -10.2%.
The biggest single holding is ATRA (~$11.2M) as 10% Owner. The recent filings there lean toward selling, a net 6,219 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Jan 12, 2026 | ATRA Atara Biotherapeutics, Inc. | 10% Owner | Sell | 80,554 | $6.07 | $489,019.17 | -5.7% | -20.9% | - | |
| Aug 15, 2025 | ATRA Atara Biotherapeutics, Inc. | 10% Owner | Buy | 55,000 | $12.19 | $670,422.50 | +4.1% | +9.0% | - | |
| Jul 17, 2025 | ATRA Atara Biotherapeutics, Inc. | 10% Owner | Buy | 19,335 | $9.64 | $186,372.00 | +1.5% | +57.4% | -10.2% |